CJC-1295 vs Ipamorelin
CJC-1295 and Ipamorelin are frequently discussed together — and often used in combination — for growth hormone optimization. They work through complementary mechanisms, which is why the combination is one of the most popular peptide pairings. Understanding how each works individually helps explain why they are often paired.
CJC-1295
A growth hormone-releasing hormone analog that stimulates the pituitary gland to produce more growth hormone.
Ipamorelin
A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin.
| Category | CJC-1295 | Ipamorelin |
|---|---|---|
| Mechanism | GHRH receptor agonist (amplifies GH release signal) | Ghrelin receptor agonist (triggers GH release) |
| Evidence Level | Moderate — Phase II clinical trials exist | Moderate — human pharmacodynamic studies exist |
| Selectivity | Specific to GHRH pathway | Highly selective — minimal cortisol/prolactin effects |
| Half-Life | With DAC: ~6-8 days. Without DAC: ~30 minutes | ~2 hours |
| Common Side Effects | Water retention, tingling, flushing | Mild water retention, head rush, increased appetite |
| Typical Use | Often combined with Ipamorelin | Often combined with CJC-1295 |
Summary
CJC-1295 and Ipamorelin work through different but complementary pathways to stimulate growth hormone release. CJC-1295 amplifies the GHRH signal (like turning up the volume), while Ipamorelin provides the secretagogue trigger (like pressing the play button). Together, they produce a synergistic effect that is generally greater than either alone. The combination is considered one of the better-tolerated GH optimization approaches because Ipamorelin's selectivity helps minimize side effects that other secretagogues might cause. However, any GH optimization protocol requires clinician supervision and regular lab monitoring.
These peptides are often used together. See our stack profiles for combination details.